178 related articles for article (PubMed ID: 35469547)
41. 1,25(OH)
Tang J; Gu L; Luo J; Luo H; Zeng Q; Jiang Y
Int Immunopharmacol; 2022 Nov; 112():109266. PubMed ID: 36174418
[TBL] [Abstract][Full Text] [Related]
42. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
43. Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
Ito Y; Hsu MF; Bettaieb A; Koike S; Mello A; Calvo-Rubio M; Villalba JM; Haj FG
Metabolism; 2017 Nov; 76():56-69. PubMed ID: 28987240
[TBL] [Abstract][Full Text] [Related]
44. Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell.
Liu Y; Li L; Yi B; Hu ZX; Li AM; Yang C; Zheng L; Zhang H
Life Sci; 2019 Oct; 234():116755. PubMed ID: 31415769
[TBL] [Abstract][Full Text] [Related]
45. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
Shao X; Zhang X; Hu J; Gao T; Chen J; Xu C; Wei C
Exp Cell Res; 2020 Mar; 388(2):111849. PubMed ID: 31954110
[TBL] [Abstract][Full Text] [Related]
46. FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury.
Chen X; Liu W; Xiao J; Zhang Y; Chen Y; Luo C; Huang Q; Peng F; Gong W; Li S; He X; Zhuang Y; Wu N; Liu Y; Wang Y; Long H
FASEB J; 2020 Oct; 34(10):13300-13316. PubMed ID: 32786113
[TBL] [Abstract][Full Text] [Related]
47. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
48. Formyl peptide receptor 1 promotes podocyte injury through regulation of mitogen-activated protein kinase pathways.
Zhang J; Ding T; Tang D; Wang J; Huang P
Exp Biol Med (Maywood); 2022 Jan; 247(2):87-96. PubMed ID: 34565207
[TBL] [Abstract][Full Text] [Related]
49. Down-regulation of Risa improves podocyte injury by enhancing autophagy in diabetic nephropathy.
Su PP; Liu DW; Zhou SJ; Chen H; Wu XM; Liu ZS
Mil Med Res; 2022 May; 9(1):23. PubMed ID: 35614465
[TBL] [Abstract][Full Text] [Related]
50. Imbalance of autophagy and apoptosis in intestinal epithelium lacking the vitamin D receptor.
Lu R; Zhang YG; Xia Y; Sun J
FASEB J; 2019 Nov; 33(11):11845-11856. PubMed ID: 31361973
[TBL] [Abstract][Full Text] [Related]
51. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
52. Exogenous spermine attenuates diabetic kidney injury in rats by inhibiting AMPK/mTOR signaling pathway.
Zhang X; Zhang L; Chen Z; Li S; Che B; Wang N; Chen J; Xu C; Wei C
Int J Mol Med; 2021 Mar; 47(3):. PubMed ID: 33537831
[TBL] [Abstract][Full Text] [Related]
53. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
54. Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes.
Liu Y; Zhang J; Wang Y; Zeng X
Cell Death Dis; 2017 Aug; 8(8):e3006. PubMed ID: 28837139
[TBL] [Abstract][Full Text] [Related]
55. Emodin Ameliorates Renal Damage and Podocyte Injury in a Rat Model of Diabetic Nephropathy via Regulating AMPK/mTOR-Mediated Autophagy Signaling Pathway.
Liu H; Wang Q; Shi G; Yang W; Zhang Y; Chen W; Wan S; Xiong F; Wang Z
Diabetes Metab Syndr Obes; 2021; 14():1253-1266. PubMed ID: 33776462
[TBL] [Abstract][Full Text] [Related]
56. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
[TBL] [Abstract][Full Text] [Related]
57. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
Theranostics; 2021; 11(10):4728-4742. PubMed ID: 33754024
[No Abstract] [Full Text] [Related]
58. VDR regulates mitochondrial function as a protective mechanism against renal tubular cell injury in diabetic rats.
Chen H; Zhang H; Li AM; Liu YT; Liu Y; Zhang W; Yang C; Song N; Zhan M; Yang S
Redox Biol; 2024 Apr; 70():103062. PubMed ID: 38320454
[TBL] [Abstract][Full Text] [Related]
59. Swiprosin-1 Promotes Mitochondria-Dependent Apoptosis of Glomerular Podocytes via P38 MAPK Pathway in Early-Stage Diabetic Nephropathy.
Wang RM; Wang ZB; Wang Y; Liu WY; Li Y; Tong LC; Zhang S; Su DF; Cao YB; Li L; Zhang LC
Cell Physiol Biochem; 2018; 45(3):899-916. PubMed ID: 29421811
[TBL] [Abstract][Full Text] [Related]
60. Renoprotective role of the vitamin D receptor in diabetic nephropathy.
Zhang Z; Sun L; Wang Y; Ning G; Minto AW; Kong J; Quigg RJ; Li YC
Kidney Int; 2008 Jan; 73(2):163-71. PubMed ID: 17928826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
